Showing 3591-3600 of 6951 results for "".
- Ventyx Biosciences Halts Trial for Experimental Psoriasis Drughttps://practicaldermatology.com/news/ventyx-biosciences-halts-trial-for-experimental-psoriasis-drug/2462116/Ventyx Biosciences has announced it is halting development of an experimental psoriasis drug due to missed internal targets required for it to advance beyond Phase 2, according to the company. The drug, VTX958, had shown acceptable safety and efficacy, and had achevied with its 225 mg B
- ‘Bliss’ Compound May Hold Out Hope for Autoimmune Skin Diseasehttps://practicaldermatology.com/news/bliss-compound-may-hold-out-hope-for-autoimmune-skin-disease/2462112/A marijuana-like compound holds out promise as a new treatment for a severe autoimmune skin disease called skin lupus, suggests a recent study out of George Washington University. If the results of the mouse study can be replicated in human trials, the compound, known as anandamide
- Survey: Americans with Mild-to-Moderate Acne Have Defeatist Attitudes About Treatment, Despite Self-Consciousnesshttps://practicaldermatology.com/news/sun-pharma-survey-reveals-americans-with-mild-to-moderate-acne-have-defeatist-attitudes-about-treatment-despite-self-consciousness/2462110/A new survey reveals defeatist attitudes about treatment among people with mild-to-moderate acne, despite feelings of self-consciousness. Among the 1,003 survey respondents ages 13-55, only three in 10 reported having seen a dermatologist, suggesting that many people with mild-to-moderate acne ar
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade.</
- Study Highlights Potential Minoxidil Shortagehttps://practicaldermatology.com/news/study-highlights-potential-minoxidil-shortage/2462107/Minoxidil may be in short supply at some pharmacies, potentially jeopardizing patients’ efforts to treat hair loss, according to new research in the
- Healiva, C4U Join Forces to Develop New Gene Therapy for EBhttps://practicaldermatology.com/news/healiva-c4u-join-forces-to-develop-new-gene-therapy-for-eb/2462106/Healiva SA (Healiva) and C4U Corporation (C4U) have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa (EB), also known as “butterfly children”. “The collaboration aims to provide
- Study Validates Long-Term Safety of Delgocitinib Cream in Adults With Chronic Hand Eczemahttps://practicaldermatology.com/news/study-validates-long-term-safety-of-delgocitinib-cream-in-adults-chronic-hand-eczema/2462105/LEO Pharma’s Delgocitinib Cream was well-tolerated in adults with moderate to severe chronic hand eczema (CHE), according to results from the DELTA 3 Open-Label Extension Trial. What’s more, patients who entered the DELTA 3 trial after receiving delgocitinib cream
- Almirall Highlights World Psoriasis Day With the Nina Serieshttps://practicaldermatology.com/news/world-psoriasis-day/2462102/October 29, 2023 is World Psoriasis Day, and Almirall is highlighting the impact of this disease on the wellbeing of individuals, their families, and friends through the series Nina, and with the support of the International Federation of Psoriasis Associations. Nina
- UCSF's HS PROGRESS Aims to Shed Light on Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucsfs-hs-progress-aims-to-shed-light-on-hidradenitis-suppurativa/2462092/University of California-San Francisco (UCSF) is leading HS PROGRESS (Hidradenitis Suppurativa [HS] Prospective Observational Registry and bioSpecimen repoSitory), a multicenter, longitudinal study that aims to comprehensively characterize HS from clinical and biological perspectives. <
- Almost Half of All Skin Disease Patients Report Sleep Issueshttps://practicaldermatology.com/news/almost-half-of-all-skin-disease-patients-report-sleep-issues/2462075/Almost half of all patients with skin disease report sleep disturbances, finds new research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The ALL PROJECT analyzed data on more than 50,000 adults across 20 countries to assess the impact